1. Medtech Insight

CRT 2018: Late-Breakers Feature Sapien MR, Selution DCB, Low-Risk TAVR, and Radial Access PCI

 
• By Reed Miller

The late-breaking trials presented at the 2018 CRT Conference in Washington, DC, March 3-6 included new clinical data on novel drug-eluting coronary stents, endovascular peripheral vascular interventions, and transcatheter heart valve devices, plus a major trial comparing transfemoral and transradial coronary interventions.

Washington DC Capitol dome detail with waving american flag
CRT is an annual four-day conference featuring new data and vascular intervention technology held in Washington, DC

The first-in-human study of Edwards' Sapien M3 transseptal transcatheter mitral valve replacement device shows it is a feasible option for patients with severe mitral regurgitation who would be at high risk during open mitral-valve surgery. John Webb of St. Paul's Hospital in Vancouver presented the results of the first 10 cases with Sapien M3 during a late-breaking trial-session at the CRT meeting on March 5.

Sapien M3 is a combination of Edwards' successful 29 mm Sapien 3 transcatheter aortic valve and a unique nitinol docking device that adapts it for the mitral valve. The valve is compatible with a 20f eSheath delivery device and has a knitted polyethylene terephthalate skirt to create a seal between the native leaflets and the dock

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D